Invitae (NYSE:NVTA) Now Covered by Analysts at StockNews.com
by Doug Wharley · The Cerbat GemStockNews.com initiated coverage on shares of Invitae (NYSE:NVTA – Free Report) in a report issued on Wednesday morning. The firm issued a hold rating on the medical research company’s stock.
Invitae Stock Performance
Shares of NYSE NVTA opened at $0.02 on Wednesday. Invitae has a 52-week low of $0.02 and a 52-week high of $0.02. The firm has a 50 day moving average price of $0.25 and a two-hundred day moving average price of $0.52. The stock has a market cap of $4.51 million, a P/E ratio of 0.00 and a beta of 1.59.
Institutional Investors Weigh In On Invitae
Institutional investors have recently modified their holdings of the company. Veritable L.P. bought a new stake in shares of Invitae in the 1st quarter valued at $25,000. Versor Investments LP bought a new stake in shares of Invitae in the 2nd quarter valued at $27,000. SG Americas Securities LLC bought a new stake in shares of Invitae in the 3rd quarter valued at $29,000. Private Advisor Group LLC boosted its stake in shares of Invitae by 114.1% in the 2nd quarter. Private Advisor Group LLC now owns 25,012 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 13,330 shares during the last quarter. Finally, Interchange Capital Partners LLC boosted its stake in shares of Invitae by 67.0% in the 2nd quarter. Interchange Capital Partners LLC now owns 30,459 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 12,219 shares during the last quarter. 61.28% of the stock is owned by institutional investors.
About Invitae
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.